# PT-141 (Bremelanotide) FAQ — Common Questions about the FDA-Approved Melanocortin Agonist > Direct answers to the most common questions about bremelanotide (PT-141): mechanism, label dose, RECONNECT trials, safety, off-label use, and how it differs from PDE5 inhibitors. **Common questions about PT-141, answered from the trial record** Pulled from the most frequently searched bremelanotide questions and the points where the literature is most often misread. ## What is PT-141 (bremelanotide)? PT-141 is the research code name for bremelanotide, a synthetic cyclic seven-amino-acid peptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) [1]. Bremelanotide is the International Nonproprietary Name (INN); PT-141 is the development code. They refer to the same molecule. It was FDA-approved in June 2019 (NDA 210557) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) and is administered as a 1.75 mg subcutaneous injection on-demand [9]. ## How does PT-141 work in the brain? Bremelanotide is a non-selective melanocortin-receptor agonist whose primary therapeutic activity is at MC4R, the melanocortin-4 receptor, in the hypothalamus [5][16]. The proposed model is that MC4R agonism on hypothalamic dopaminergic neurons (medial preoptic area, ventral tegmental area, nucleus accumbens) increases dopamine release in mesolimbic reward circuitry, while concurrent action on amygdala and cortico-limbic networks reduces the cognitive self-monitoring that dampens erotic processing in HSDD [5][16]. Thurston and colleagues confirmed central effects directly with fMRI in 31 women with HSDD: a single dose increased self-reported desire for up to 24 hours and measurably modulated erotica-evoked brain activity [5]. ## What is the FDA-approved dose, and how often can it be used? The label specifies a single 1.75 mg subcutaneous injection in the abdomen or thigh via single-use autoinjector, at least 45 minutes before anticipated sexual activity [9]. Two additional limits apply: at most one dose in any 24-hour period, and at most eight doses in any 28-day period [9][11]. The label also recommends discontinuation after eight weeks if no improvement is reported. There is no titration schedule and no maintenance regimen — the on-demand model is the regimen. ## What did the RECONNECT Phase 3 trials show? RECONNECT was the umbrella name for two identically-designed pivotal trials (Studies 301 and 302; NCT02333071 and NCT02338960) enrolling 1,202 premenopausal women with HSDD [1]. Over 24 weeks, 1.75 mg subcutaneous bremelanotide produced a least-squares mean change vs placebo of +0.35 on the FSFI-Desire domain and -0.33 on FSDS-DAO Item 13 (distress), both at P<0.0001 [1]. A 52-week open-label extension found no new safety signals and continued symptom improvement [2]. A 2025 secondary-endpoint analysis showed FSFI arousal scores improved 23-25% over baseline at four weeks (vs 5-10% on placebo) and orgasm scores 16-21% (vs 0-9%) [14]. ## What are the side effects of PT-141? The two dominant adverse events are nausea (about 40% of users vs ~1% on placebo, median onset within one hour post-dose, median duration ~2.4 hours) and flushing (~20% vs ~1%) [3][12]. Headache (~11-12%), injection-site reactions (~5%), and a small transient blood-pressure increase (roughly +3 mmHg systolic, resolving within 8-12 hours) round out the common profile [3][10]. Focal hyperpigmentation — discrete darkening of skin, gums, or breasts — was reported in roughly 1% of patients and is the rationale for the eight-doses-per-month cap [11]. Nausea is the most common cause of discontinuation [3]. ## Who should not use PT-141? Per the US label, bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease, and not recommended in patients at high cardiovascular risk (smoking, diabetes, obesity, dyslipidemia, age) [10]. It is approved only for premenopausal women with acquired, generalized HSDD — not for postmenopausal women, not for men, and not for sexual enhancement in unaffected individuals [9]. The label notes a drug-drug interaction with naltrexone (bremelanotide may render naltrexone subtherapeutic in patients taking it for opioid- or alcohol-use disorder) [9]. ## How long before sexual activity should PT-141 be given? The label recommends administration at least 45 minutes before anticipated sexual activity [9]. This aligns with the pharmacokinetics: median Tmax is approximately 1.0 hour after subcutaneous injection, and onset of pharmacologic effect typically occurs within 45-60 minutes [9]. Self-reported desire benefit and central neuroimaging effects have been measurable for up to 24 hours after a single dose, though the label does not characterize the drug as a 24-hour treatment [5]. ## What is the difference between PT-141 and PDE5 inhibitors like sildenafil? They work in different places by different mechanisms on different parts of sexual response. PDE5 inhibitors act peripherally on penile smooth muscle to enhance the vascular machinery of erection — they enable arousal that is already present. Bremelanotide acts centrally at hypothalamic MC4R to increase the appetitive, motivational component of sexual response — it is a desire drug, not a vasodilator [5][16]. The two mechanisms are complementary, not redundant: a 2005 crossover study showed 7.5 mg intranasal PT-141 plus 25 mg oral sildenafil produced a greater erectile response in sildenafil-responsive men than sildenafil alone [8], and a Phase 2 trial of a co-formulated bremelanotide + PDE5 inhibitor for ED was initiated in June 2024 [19]. ## What does the research say about PT-141 in men? The drug is not FDA-approved for any indication in men. The historical male data come from the early 2000s intranasal program: Diamond and colleagues showed dose-dependent, statistically significant pro-erectile response above 7 mg intranasal in healthy men and men with mild-to-moderate ED [7], and a follow-up demonstrated additive effect with low-dose sildenafil [8]. After intranasal development was discontinued for blood-pressure reasons, the female HSDD program advanced to approval [19]. A Phase 2 trial of a subcutaneous bremelanotide + PDE5 inhibitor combination in men with ED was initiated in June 2024, with topline targeted for the first half of 2026 [19]. Until those data report, off-label use in men is not supported by adequately powered modern clinical trials. ## Is PT-141 being studied for anything other than sexual desire? Yes — obesity is the most active program. Phase 1 trials in obese premenopausal women had shown bremelanotide produced approximately 1.3-1.7 kg greater weight loss than placebo over 16 days, driven by an approximately 400 kcal/day caloric reduction [13]. The 2025 Phase 2 BMT-801 trial reported that low-dose bremelanotide produced appetite-suppression scores comparable to tirzepatide (71% vs 73% improvement on a validated daily appetite questionnaire) and substantially blunted the appetite rebound otherwise seen on tirzepatide discontinuation, supporting development as both a co-administered and a maintenance therapy [17]. Separately, a 2024 in vitro study identified MC3R/MC4R as candidate oncology targets in glioblastoma cells [15]. The oncology work is preclinical. ## Is research-chemical PT-141 the same as the approved product? Pharmacologically, the molecule is the same — bremelanotide is bremelanotide regardless of where the powder came from. Clinically, the contexts are not equivalent. The approved injectable product is a pharmaceutical-grade sterile aqueous solution in a single-use 0.3 mL autoinjector containing exactly 1.75 mg bremelanotide (as 1.89 mg of the acetate salt), manufactured under FDA-regulated current Good Manufacturing Practice (cGMP) [9]. Research-chemical PT-141 sold by non-pharmacy vendors is not manufactured under cGMP, has not been tested for sterility, identity, potency, or contaminants to pharmaceutical standards, and is sold for laboratory research purposes only. The FDA approval applies to the specific approved formulation, not to the molecule sold by any source. ## Why is the dose capped at eight per month? Because of focal hyperpigmentation. Discrete darkening of skin (commonly on the face), gums, or breasts was reported in approximately 1% of bremelanotide-treated patients in Phase 3 trials, and risk increased with more than eight doses in any 28-day period [11]. The mechanism is MC1R activation on cutaneous melanocytes — a predictable consequence of non-selective melanocortin agonism — and the pigmentation may not fully reverse on discontinuation. The eight-per-month cap is the dose-finding compromise that keeps cumulative MC1R exposure low enough to make focal hyperpigmentation rare [11]. ## Why does bremelanotide cause nausea so often? Nausea is the most common adverse event of melanocortin-pathway agonism in general, not unique to bremelanotide. It begins within about one hour post-dose (close to Cmax), lasts a median of about 2.4 hours, and is usually mild-to-moderate and self-limiting [12]. Antiemetics are not part of the labeled regimen. About 40% of users in Phase 3 reported nausea versus ~1% on placebo, and nausea is the most common reason for discontinuation [3]. The Phase 2 obesity work is exploring lower doses that retain appetite-suppression efficacy while reducing nausea, which would represent a meaningful improvement in tolerability for both indications [17]. ## Is PT-141 a controlled substance? Is it banned in sport? Bremelanotide is not a controlled substance under the US Controlled Substances Act. It is also not currently listed on the WADA Prohibited List, though melanocortin pathway agonists are pharmacologically active central nervous system agents and athletes should verify status with their relevant governing body before any use. It is not approved by the European Medicines Agency. ## References [1] Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019. — doi: 10.1097/AOG.0000000000003500 — https://pubmed.ncbi.nlm.nih.gov/31599839/ [2] Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology. 2019. — doi: 10.1097/AOG.0000000000003514 — https://pubmed.ncbi.nlm.nih.gov/31599847/ [3] Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women's Health. 2022. — doi: 10.1089/jwh.2021.0191 — https://pubmed.ncbi.nlm.nih.gov/35230116/ [5] Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, Muzi B, Patel B, Alexander EC, Suladze S, Modi M, Eng PC, Bassett PA, Abbara A, Goldmeier D, Comninos AN, Dhillo WS. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of Clinical Investigation. 2022. — doi: 10.1172/JCI152341 — https://www.jci.org/articles/view/152341 [7] Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004. — doi: 10.1038/sj.ijir.3901139 — https://www.nature.com/articles/3901139 [8] Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005. — doi: 10.1016/j.urology.2004.10.060 — https://pubmed.ncbi.nlm.nih.gov/15833522/ [9] Bremelanotide injection US Prescribing Information. US FDA Approved Label, NDA 210557. 2019. — https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [10] Bremelanotide Prescribing Information: Section 5 Warnings and Precautions. US FDA Approved Label, NDA 210557. 2019. — https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [11] Bremelanotide Prescribing Information: Section 5.2 Focal Hyperpigmentation. US FDA Approved Label, NDA 210557. 2019. — https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [12] Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology International. 2022. — doi: 10.3390/neurolint14010006 — https://www.mdpi.com/2035-8377/14/1/6 [13] Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, Obesity and Metabolism. 2022. — doi: 10.1111/dom.14672 — https://pubmed.ncbi.nlm.nih.gov/35170192/ [14] RECONNECT investigators. Positive Effects of Bremelanotide on Female Sexual Arousal and Orgasm in Premenopausal Women with HSDD: FSFI Data from the RECONNECT Trials. The Journal of Sexual Medicine (Supplement). 2025. — doi: 10.1093/jsxmed/qdaf068.108 — https://academic.oup.com/jsm/article/22/Supplement_1/qdaf068.108/8119524 [15] Suzuki S, Kitanaka C, Okada M. Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. Anticancer Research. 2024. — doi: 10.21873/anticanres.17214 — https://pubmed.ncbi.nlm.nih.gov/39197897/ [16] Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums. 2022. — doi: 10.1017/S109285292000219X — https://pubmed.ncbi.nlm.nih.gov/33455598/ [17] Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide (BMT-801). Sponsor press release. 2025. — https://palatin.com/press_releases/palatin-reports-positive-appetite-suppression-results-from-phase-2-obesity-study-of-mc4r-agonist-bremelanotide-and-tirzepatide/ [19] Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019. (Regulatory history review; also covers initiation of the Phase 2 co-administered bremelanotide + PDE5i ED trial, June 2024.) — doi: 10.1007/s40265-019-01187-w — https://link.springer.com/article/10.1007/s40265-019-01187-w --- Not medical advice. This site does not sell any product and is not affiliated with any vendor or manufacturer.